Johnson & Johnson (NYSE:JNJ) said that new phase 1b data found that candidate bleximenib demonstrated antileukemic activity.
The selective menin inhibitor, in combination withVenclexta (venetoclax) and Vidaza (azacitidine), is under investigation for acute myeloid leukemia in individuals with certain genetic mutations.
The dose-finding study enrolled newly diagnosed, intensive chemo-ineligible AML, and relapsed or refractory AML patients.
J&J noted that bleximenib’s safety profile was good, with no QTc prolongation signal, no events of Grade 3 or higher, and only three Grade 1 events at the recommended phase 2 dose.
